RE:RE:US side of tradingIf we get good clinical data in 2 weeks, this will allow us to have Accelerated Approval, which would allow us to get revenues from the remaining patients of our Ph. 2. That would be another factor that an intereted big pharma would find attractive. Such AA would also allow us to be a bit more independent while we negociate.
It has never happened in the FDA history that a Breakthrough designation winner was left on the sideline. Even less with a AA winner.
That's why it's so important to assess how good our optimized group of patients delivers in terms of efficacy %, notwithstanding the first 12 undertreated patients.